The world’s first vaccine against the dangerous dengue fever is now available at clinics and private hospitals in Indonesia. The vaccine was produced and launched by Sanofi Pasteur, a multinational pharmaceutical company that specializes in the production of vaccines; it has also been approved by the Indonesian Drug and Food Regulation Agency (BPOM) for children aged 9 to 16 years as a precaution against the 4 serotypes of dengue fever.
There has been a recent dramatic 17% increase in dengue fever recently, which is a form of hemorrhagic fever that is transmitted via the bite of the Aedes mosquito. In 2015, a total of 129,000 cases of DBD were recorded in Indonesia in 2015, a number that is seen to be increasing in 2016.
Results have shown that the new vaccine is capable of preventing high hospitalization rates associated with DBD with a period of effectiveness of up to four years.
The use of the vaccine has now been initially approved in 12 countries: Mexico, Peru, Indonesia, the Philippines, Brazil, El Salvador, Costa Rica, Paraguay, Guatemala, Thailand, Singapore, and Bolivia.